This site is intended for U.S. health care professionals only.
14.6-month median PFS (95% CI: 5.9-20.1) with LENVIMA + everolimus vs 5.5 months (95% CI:
3.5-7.1) with everolimus alone (HR: 0.37 [95% CI: 0.22-0.62]); major efficacy endpoint1
PFS=progression-free survival; HR=hazard ratio; CI=confidence
interval; aRCC=advanced renal cell carcinoma; AR=adverse
reaction; MOA=mechanism of action.
See efficacy data
Help manage ARs
See details on another treatment for advanced renal cell carcinoma
Not an actual patient